百奥泰：贝伐珠单抗的欧美销售由合作伙伴主导推进

Core Viewpoint - The company is actively preparing for the commercialization of its products in Europe, with a focus on collaboration with partners to expedite market entry [1] Group 1: Product Sales Progress - The sales of Bevacizumab in Europe and the U.S. will be primarily driven by the company's partners [1] - The commercialization efforts for Tocilizumab and Ustekinumab in Europe are also in active preparation [1] - The company emphasizes ongoing close collaboration with partners to accelerate overseas market expansion [1]